Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading RNA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.78%71.011.0%$662.14m
AMGNAmgen Inc.
0.57%154.670.8%$509.58m
CELGCelgene Corporation
-0.85%112.661.0%$466.03m
ARIAARIAD Pharmaceuticals, Inc.
0.21%23.7516.4%$442.07m
BIIBBiogen Inc.
0.11%280.661.0%$398.14m
REGNRegeneron Pharmaceuticals, Inc.
-0.23%362.562.5%$365.69m
ALXNAlexion Pharmaceuticals, Inc.
-1.77%131.972.5%$347.73m
ILMNIllumina, Inc.
-0.52%159.743.8%$229.47m
CLVSClovis Oncology, Inc.
2.07%58.2917.9%$160.24m
INCYIncyte Corporation
-0.26%117.222.2%$158.22m
VRTXVertex Pharmaceuticals Incorporated
0.57%81.372.1%$144.14m
TSROTESARO, Inc.
-1.94%147.0015.0%$106.77m
IONSIonis Pharmaceuticals, Inc.
0.58%46.978.9%$101.63m
SRPTSarepta Therapeutics, Inc.
-4.59%32.6616.8%$101.57m
BMRNBioMarin Pharmaceutical Inc.
-1.78%84.624.9%$95.71m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.